The AJMC® clinical page includes all the published content across AJMC.com, The American Journal of Managed Care® and Evidence-Based Oncology™ on a variety of specialties, including dermatology, cardiology, oncology, and rheumatology.
December 27th 2024
Advances in therapy are improving outcomes for patients, but the incidence and mortality rates for hepatocellular carcinoma are increasing in the US.
HER2 Amplification Shows Prognostic Capabilities in mCRC
August 28th 2023Although HER2 amplification showed prognostic capabilities in patients with RAS wild-type metastatic colorectal cancer (mCRC), it was not predictive of survival benefit as a first-line treatment option in combination with panitumumab vs standard-of-care bevacizumab.
Read More
Study Suggests CAR T-Cell Therapy Safe, Effective After Allo-SCT in Multiple Myeloma
August 26th 2023A retrospective analysis of the CARTITUDE-1 trial suggests that patients who have undergone allogeneic stem cell transplant (allo-SCT) prior to receiving chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma experience comparable outcomes to allo-SCT–naïve patients.
Read More
Combining Surgery and Biologic Therapy Improves Outcomes in Patients With CRSwNP
August 26th 2023Combination endoscopic sinus surgery (ESS) and biological therapy significantly decreased polyp burden in refractory chronic rhinosinusitis with nasal polyposis (CRSwNP) compared with biologic therapy alone
Read More
Second-Line Axi-Cel Produces Complete Metabolic Responses in Transplant-Ineligible LBCL
August 24th 2023Second-line treatment with axicabtagene ciloleucel (axi-cel) led to an investigator-assessed, 3-month complete metabolic response rate of 71.0% in patients with large B-cell lymphoma (LBCL) who were ineligible for autologous stem cell transplant.
Read More
Dr Jennifer Brown Discusses Zanubrutinib Uptake in CLL, SLL
August 23rd 2023Jennifer Brown, MD, PhD, director of the Chronic Lymphocytic Leukemia Center at Dana-Farber Cancer Institute, discussed the uptake of zanubrutinib for the treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL).
Watch